Compare Li Auto Inc (LI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Sanofi SA — how do they compare? Li Auto Inc trades at $12.62 (market cap $12.28B), while Sanofi SA trades at $43.63 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 8.5× Li Auto Inc's market cap, and Sanofi SA pays a 5.55% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| LI | SNY | |
|---|---|---|
Market Cap | $12.28B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.69 | $52.34 |
52-Week Low | $11.74 | $41.33 |
Enterprise Value | $1.11B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.84, down 0.85% on the day, with bearish technical signals and mixed earnings performance. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle launches including the Li L6 and L8 aim to boost deliveries amid intense Chinese EV competition.
While analyst consensus suggests moderate upside to $14.80 price target, significant risks include declining profitability, negative cash flow trends, and competitive pressures in China's EV market. The stock faces headwinds from execution challenges and macroeconomic uncertainties affecting the auto sector.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
